onabotulinumtoxin a treatment of drooling in children with cerebral palsy: a prospective, longitudinal open-label study

Clicks: 315
ID: 197807
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #101 of 300 articles by views in matec web of conferences

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 300 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The aim of this prospective open-label study was to treat disabling drooling in children with cerebral palsy (CP) with onabotulinumtoxin A (A/Ona, Botox®) into submandibular and parotid glands and find the lowest effective dosage and least invasive method. A/Ona was injected in 14 children, Mean age 9 years, SD 3 years, under ultrasonic guidance in six successive Series, with at least six months between injections. Doses and gland involvement increased from Series A to F (units (U) per submandibular/parotid gland: A, 10/0; B, 15/0; C, 20/0; D, 20/20; E, 30/20; and F, 30/30). The effect was assessed 2, 4, 8, 12, and 20 weeks after A/Ona (drooling problems (VAS), impact (0–7), treatment effect (0–5), unstimulated whole saliva (UWS) flow and composition)) and analyzed by two-way ANOVA. The effect was unchanged–moderate in A to moderate–marked in F. Changes in all parameters were significant in E and F, but with swallowing problems ≤5 weeks in 3 of 28 treatments. F had largest VAS and UWS reduction (64% and 49%). We recommend: Start with dose D A/Ona (both submandibular and parotid glands and a total of 80 U) and increase to E and eventually F (total 120 U) without sufficient response.
Reference Key
mller2015toxinsonabotulinumtoxin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eigild Møller, Søren Anker Pedersen, Pablo Gustavo Vinicoff, Allan Bardow, Joan Lykkeaa, Pia Svendsen, Merete Bakke
Are you one of these authors? Claim your profile
Journal matec web of conferences
Year 2015
DOI
10.3390/toxins7072481
URL
http://www.mdpi.com/2072-6651/7/7/2481
Keywords
botulinum toxin cerebral paresis childrenmedicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.